Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-914143 (Peginterferon Lambda-1a), Pegylated-Interferon-lambda, pegIFNλ, Peginterferon Lambda-1a, PegIFN lambda, Pegylated interferon lambda (pegIFNλ), Pegylated Interferon Lambda-1a
BMS-914143 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group 1: BMS-914143 (eGFR ≥ 80 mL/min/1.73 m2) | EXPERIMENTAL | BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2 |
| Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2) | EXPERIMENTAL | BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with mild renal dysfunction with eGFR 60 to 79 mL/min/1.73 m2 |
| Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2) | EXPERIMENTAL | BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with moderate renal dysfunction with eGFR 30 to 59 mL/min/1.73 m2 |
| Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2) | EXPERIMENTAL | BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with severe renal dysfunction with eGFR 15 to 29 mL/min/1.73 m2 |
| Group 5: BMS-914143 (eGFR < 15 mL/min/1.73 m2) | EXPERIMENTAL | BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with end-stage renal dysfunction with eGFR \< 15 mL/min/1.73 m2 (on hemodialysis \[HD\] or non-HD) |
| Name | Type | Description |
|---|---|---|
| BMS-914143 (Peginterferon Lambda-1a) | BIOLOGICAL | - |
Inclusion Criteria: * Normal renal function or mild, moderate, severe or end-stage renal dysfunction Exclusion Criteria: * History of uncontrolled or unstable cardiovascular, respiratory, gastrointestinal, hepatic, endocrine, hematopoietic, psychiatric or neurological conditions within 6 months o...
BMS-914143 is an investigational monoclonal antibody developed by Bristol-Myers Squibb for chronic hepatitis B virus infection. It has completed a single Phase 1 clinical trial. It is also known as peginterferon lambda-1a. The drug has not been approved and remains in clinical development.
BMS-914143 is being studied for the treatment of chronic hepatitis B virus infection. The one completed trial also enrolled participants with chronic hepatitis C virus infection as a listed condition. It is investigational and has not been approved for any use.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, develops BMS-914143. The company sponsored the Phase 1 pharmacokinetic study of the drug conducted in the United States.
BMS-914143 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The drug is investigational and has not received FDA approval for chronic hepatitis B virus infection or any other indication.
BMS-914143 has been studied in one completed Phase 1 trial, NCT01708889. That trial was a pharmacokinetic study of BMS-914143 in participants with normal renal function and mild, moderate, severe, and end-stage renal dysfunction. It enrolled 43 participants in the United States and included healthy volunteers.
Yes, BMS-914143 is also known as peginterferon lambda-1a. Both names refer to the same investigational Bristol-Myers Squibb compound studied in chronic hepatitis B virus infection. Searches for either name lead to the same drug asset and the same completed Phase 1 trial, NCT01708889.